A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of sequential administration of Tarceva and
gemcitabine/platinum chemotherapy in patients with stage IIIb/IV non-small cell lung cancer.
Patients will be randomized to receive Tarceva (150 mg po) or placebo on days 15-28 of a 4
week cycle of intravenous platinum-based chemotherapy, for a total of 6 cycles. The
anticipated time on study treatment is until disease progression or unacceptable toxicity.